C
SPRY icon

Covestor’s ARS Pharmaceuticals SPRY Stock Holding History

Covestor’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Hold
7
– – ﹤0.01% 2734
2025
Q4 		$0 Sell
7
-1
-13% -$10 ﹤0.01% 2707
2025
Q3 		$0 Hold
8
– – ﹤0.01% 2736
2025
Q2 		$0 Hold
8
– – ﹤0.01% 2722
2025
Q1 		$0 Hold
8
– – ﹤0.01% 2692
2024
Q4 		$0 Sell
8
-3
-27% -$42 ﹤0.01% 2701
2024
Q3 		$0 Sell
11
-1
-8% -$12 ﹤0.01% 2724
2024
Q2 		$0 Buy
+12
New +$106 ﹤0.01% 2717

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Covestor's SPRY Position: Q1 2026 in Review

Covestor held its ARS Pharmaceuticals (SPRY) position steady in Q1 2026 at 7 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2734.

Covestor first reported a position in SPRY in Q2 2024 and has held it in 8 quarters since. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Covestor held 7 shares of ARS Pharmaceuticals worth $0 as of Q1 2026.
  • Covestor left its ARS Pharmaceuticals share count unchanged in Q1 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Covestor's portfolio in Q1 2026, its #2734 holding.
  • Covestor first reported a position in ARS Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Covestor's 13F filing for Q1 2026, filed 5 May 2026.